Accessibility Menu
Genmab A/s logo

Genmab A/s(NASDAQ) GMAB

Current Price$28.38
Market Cap$16.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+679%
5 Year-37%
1 Year+28%
1 Month+10%
Genmab A/s last closing stock price
MetricPriceDate
Last closeUSD 27.912026-07-20
Genmab A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.09%USD 28.802026-07-13
1 month+10.45%USD 25.272026-06-18
3 month+3.14%USD 27.062026-04-21
Year to date-9.38%USD 30.802025-12-31
1 year+27.56%USD 21.882025-07-18
3 year-32.89%USD 41.592023-07-21
5 year-36.78%USD 44.152021-07-21
Since inception+678.96%USD 3.582013-06-03

Genmab A/s Financials at a Glance

Market Cap

$16.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.90B

Net Income (TTM)

$821.03M

EPS (TTM)

$1.33

P/E Ratio

20.84

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$28.38

Volume

467,848.351

Open

$28.05

Previous Close

$27.91

Daily Range

$27.98 - $28.55

52-Week Range

$21.00 - $35.43

Estimated Earnings Date

Aug 6, 2026

GMAB News

Person checking medicine on a shelf in a pharmacy

Why Genmab Stock Popped on Friday

Eric VolkmanOct 3, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Was Marching Higher Today

Eric VolkmanSep 30, 2025
Person in a lab gazing into a microscope

Why Genmab Stock Smashed It on Monday

Eric VolkmanJun 2, 2025
DNA genetic sequencing biotech.jpg

Genmab Revenue Surges 18% in Q3

Motley Fool Markets TeamNov 6, 2024
cash-prescription-drugs-getty

AbbVie Signs $3.9 Billion Oncology Deal with Genmab

Cory RenauerJun 10, 2020
stock chart

Are There Good Investments Among 2019's Biotech IPOs?

David HaenOct 2, 2019

GMAB: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genmab A/s

Genmab A/S is a biopharmaceutical company based in Copenhagen, Denmark, specializing in the discovery and development of innovative antibody therapies for cancer and other serious diseases. Founded in 1999, Genmab has established a strong portfolio of commercialized products and a robust pipeline of investigational medicines.

Products and Services
  • DARZALEX, a treatment for multiple myeloma and other blood cancers
  • Teprotumumab, indicated for thyroid eye disease
  • Amivantamab, targeting advanced gastric and non-small cell lung cancers
Growth Outlook
  • Recent quarterly revenue reached $899 million, indicating strong market demand
  • Pipeline includes multiple products in late-stage clinical trials, enhancing future revenue potential
  • Strategic collaborations with major pharmaceutical companies support ongoing research and development
Financial Highlights
  • Trailing twelve-month revenue of $3.9 billion reflects consistent growth
  • Net income for the latest quarter was $53 million, showcasing profitability
  • Current ratio of 2.18 indicates strong liquidity position
Genmab A/S has positioned itself as a leader in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. The company's diverse product offerings and promising pipeline suggest a strong potential for future growth. Recent financial performance highlights, including substantial revenue and net income, further underscore the company's stability and market presence. With strategic partnerships and a commitment to research and development, Genmab is well-equipped to navigate the evolving landscape of the biopharmaceutical industry.
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,088

CEO

Jan G. J. van de Winkel, PhD

Website

www.genmab.com

Headquarters

Copenhagen, CD 1560, DK

GMAB Financials

Key Financial Metrics (TTM)

Gross Margin

38.74%

Operating Margin

13.65%

Net Income Margin

8.72%

Return on Equity

14.55%

Return on Capital

11.11%

Return on Assets

6.64%

Earnings Yield

4.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

594.94M

Volume

467.85K

Avg. Volume

1.99M

Financials (TTM)

Gross Profit

$3.64B

Operating Income

$1.29B

EBITDA

$1.24B

Operating Cash Flow

$901.34M

Capital Expenditure

-$30.00M

Free Cash Flow

$871.33M

Cash & ST Invst.

$1.52B

Total Debt

$5.35B

Genmab A/s Performance Analysis

Genmab A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,049,135,24452.0%
20232023-12-31USD 2,390,322,51516.7%
20242024-12-31USD 3,121,756,72930.6%
20252025-12-31USD 3,731,385,66719.5%
Genmab A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30778.8%
Q32025-09-3010.5%
Q42025-12-313.2%
Q12026-03-31-14.7%
Genmab A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.1761.2%
20232023-12-31USD 0.96-17.9%
20242024-12-31USD 1.7683.7%
20252025-12-31USD 1.54-12.5%
Genmab A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301100.0%
Q32025-09-3020.4%
Q42025-12-31-92.9%
Q12026-03-3180.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$899.32M

+754.6%

Gross Profit

$834.08M

+742.1%

Gross Margin

92.75%

N/A

Market Cap

$16.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.29M

N/A

Employees

2,638

N/A

Net Income

$53.20M

+85.4%

EBITDA

$186.69M

+378.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.52B

-43.7%

Total Debt

$5.35B

+3776.4%

Accounts Receivable

$1.03B

+10.8%

Inventory

$21.00M

+73.2%

Long Term Debt

$5.06B

+4008.3%

Short Term Debt

$311.00M

+1984.0%

Return on Assets

6.64%

N/A

Return on Invested Capital

11.49%

N/A

Free Cash Flow

-$2.01M

-100.8%

Operating Cash Flow

$3.01M

-99.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
THCTenet Healthcare Corporation
$197.42+1.56%
ZBHZimmer Biomet Holdings, Inc.
$89.60-0.13%
EXELExelixis, Inc.
$55.92+0.70%
SMMTSummit Therapeutics Inc.
$14.43+6.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.68+0.06%
UTZUtz Brands
$14.11+0.89%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.46+0.25%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.30-0.06%

Questions About GMAB

What is the current price of Genmab A/s?

Genmab A/s is trading at $28.38 per share.

What is the 52-week range for Genmab A/s?

Over the past 52 weeks, Genmab A/s has traded between $21.00 and $35.43.

How much debt does Genmab A/s have?

As of the most recent reporting period, Genmab A/s reported total debt of $5.35B.

How much cash does Genmab A/s have on hand?

Genmab A/s reported $1.52B in cash and cash equivalents in its most recent financial results.

What is Genmab A/s’s dividend yield?

Genmab A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services